Providing market insight, competitive analysis, and product strategy consulting services to private equity firms, early-stage companies, and the life science tools industry at large based on my 25 year professional history. Specific areas of focus: cellular analysis, 3D organoid models, and genomic tools; Life Science instrumentation/bioreagents/services; E-commerce procurement tools and scientific-focused SaaS digital platforms.

Actively oversee wealth management and make selected strategic investments for a family business portfolio comprised of real estate and agricultural holdings in Arizona, South Dakota, Texas, and Iowa with assets currently under management totaling $20M in value. Provide strategic business oversight of a 400 acre integrated farm and hog operation located in Sioux County Iowa.

I translate science into practical and usable e-commerce procurement tools that help biologists make more informed, scientifically guided decisions regarding which biological reagents to select for their research projects, with a particular focus on research antibodies.I was also a member of the senior leadership team responsible for the sale of the business to a leading PE firm (Avista Capital) in 2021. Led financial modeling, market research analysis (addressable markets, sizing, 3-5 year product roadmaps) contributing to the overall company’s corporate valuation.In this role, I applied my scientific expertise to execute a co-development partnership with a top 10 Biopharma to build and manage a multi-million revenue-generating e-commerce platform to streamline the procurement buying experience for Pharma users and enable more scientifically informed purchase decisions.- Directed user engagement groups with department heads and researchers to capture voice of customer and inform a stage-gated product development process- Identified external companies with key technologies and formed strategic partnerships to integrate value-added product selector tools into the e-commerce platform. Managed partnership deal structure, governance, project milestones, and transaction - Conversant in the Pharma e-procurement ecosystem (platforms, integrations, UI/UX) and the various pathways reagents are listed, bought, and sold within big pharma- Recruited and nurtured an ecosystem of 80+ bioreagent suppliers to participate and list their products on the eMolecules platform - Provided scientific leadership and direction to a supporting data science and IT developer team. Leveraged Agile development processes to deliver an improved user experience and drive further adoption.- Increased recurring revenue volume by 20%, doubled the engaged user base, and achieved an improved customer buying experience on the multi-million dollar generating platform.

Provided team leadership in the launch and establishment of new markets for biopharmaceutical testing using 3D bioprinted human tissues as an advanced pre-clinical model in the fields of toxicology, liver disease (NAFLD/NASH), and oncology.Cultivated and managed alliances with Pharma (Astellas, Gilead, others) to foster research collaborations, drive early adoption of company's organoid technology, and advance Organovo R&D objectives through strategic partnering- Promoted into Organovo's technical marketing team lead and led go-to-market strategy with departmental budget oversight- Provided direction internally to product development teams using a stage-gated development process to guide from initial product conception to market launch. Effected change and exerted influence by gathering consensus and aligning interests among key stakeholders (R&D, process development, GMP manufacturing, QA/QC) and ensured technical requirements aligned with market needs- Planned and managed the operational aspects of the alliance, including drafting statements of work, establishing joint governance committee(s), ensuring alliance effectiveness and health, facilitating appropriate communications, handling partner concerns, solving business problems, and negotiating with the partner on ongoing agreements.- Gathered VOC (voice of customer) and other market-based input from biopharmaceutical clients to refine the pre-clinical disease model performance, provide technical validation, and inform new product innovation process- Invited speaker at over 200 client presentations and scientific conferences domestic and internationally- Oversaw major expansion in market segments (toxicology and disease modeling), leading to >20-fold annual growth in 3 years with engagement of 20 of the top 25 biopharma companies. Developed and executed large variety of contracts totaling $8M in value during my tenure.

Developed, launched and provided direction for a service-oriented GLP-compliant laboratory providing a range of genomic assays (transcriptome-wide gene expression analysis/genome-wide DNA copy number, genotyping, and somatic mutation analysis) for basic science, cytogenetic, rare disease genomics/precision medicine, and translational/clinical research related applications- Manage and oversee the daily business operations including business development, staff training/mentorship, laboratory expansion- Responsible for approving all project reports, generating contractual documentation, expanding scale/scope of services, SOP generation/approval- Developed and maintained key relationships with academic and pharma accounts both locally and abroad- Grew laboratory operations into a $1M business(Managed concurrently with my position at Research Instruments)

Scientific and technical direction of the sales and application support teams at this leading SE Asia life science distributor- Maximized department’s technical support expertise through the development and active mentorship of 8 direct reporting field application scientists focused on providing pre- and post-sales customer support in research, drug development, bioprocessing/ manufacturing, and clinical markets across multiple APAC geographies (Singapore/Malaysia/Thailand)- Developed product positioning and application-focused scientific presentations for 30+ global life science brands including leading genomic and cellular analysis technologies- Devised instrument demo processes to support pre-sales activities and established training and technical support structures to ensure a positive post-sales customer experience and accelerated downstream reagent revenue - Expanded business through high level scientific presentations at key customer sites and conferences and through community engagement with local thought leaders at prominent academic research institutes- Invited speaker at over 500 client presentations and scientific conferences- Launched multiple new technologies into local market and led strong growth consistently meeting or exceeding departmental revenue goals ($20M)---Cell AnalysisFlow systems: Accuri C6, Amnis Imagestream, Sony Biotech - chip based sorter and spectral analyzer, Intellicyt iQue. Plate based:- High content screening systems such as Molecular Devices ImageXpress, Thermo Cellomics.- Imaging systems- Essen Incucyte, Biotek Cytation, Metasystems (cytogenetics).-Additionally, Seahorse Biosciences (mitochondrial respiration), Fluxion Biosystems (circulating tumor cells), NanoEntek (cell counting), Licor (cell and protein analysis)Genomics- Affymetrix (RNA/DNA microarray assays), Fluidigm (single cell analysis), Raindance Technologies (dPCR), Nugen (NGS sample prep), Dharmacon (RNAi/gene editing)

Provided field support for scientific applications related to RNA interference (RNAi) and genomic screening technologies and assist adapting these tools to the customer’s specific experimental workflows. Leveraged technical expertise to foster adoption and broaden market share through extensive customer consultation and technical seminars. Fostered strong revenue growth within key biotech and pharma accounts while also advancing the application of best practices within the larger screening community. Key accomplishments included facilitating the adoption of genome-wide siRNA screening libraries at a number of leading academic research institutes.

Conceived, developed, and executed innovative siRNA-based genome wide screens against oncology and inflammatory pathways using cell-based phenotypic and high content assays- Utilized high throughput and high content imaging approaches to functionally interrogate the human genome using genome-scale siRNA collections- Devised and optimized target validation assays and bioinformatic strategies for hit stratification- Identified areas of weakness within project framework and worked to mitigate these shortcomings by establishing and effectively managing several internal and external academics research collaborations- Managed and mentored summer interns and research associates

As a graduate student I worked on a number of projects pertaining to the study and functional characterization of angiogenesis in pathology and normal physiology. I developed and applied a number of innovative techniques (confocal imaging, cell junction analysis) to visualize areas of active angiogenic and vascular permeability responses in vitro and in vivo at both the cell and whole tissue level. I had a particular interest in defining the expression and characterization of the progesterone receptor in endothelial cells and relating these findings to the broader, clinically relevant issue of hormone replacement therapy (HRT) in post-menopausal women.

Characterizing mechanisms of angiogenesis in models of chronic inflammation and cancer. Mastered techniques related to small animal surgery, using lectins to label the microvasculature and preparing tissues for subsequent imaging analysis.